《新股消息》内地私人牙科服务商「美皓医疗」申请主板上市
美皓医疗集团向联交所提交主板上市申请,联席保荐人为创升融资及国金证券(香港)。
初步招股文件显示,根据市场调研机构数据,以2021年收入计集团为温州最大私人牙科服务提供商,于当地民营及整个牙科服务市场的市场份额分别约为25.2%及13.2%。
美皓医疗主要提供综合牙科服务,涵盖口腔综合治疗科、口腔修复科、种植牙科及牙齿正畸科四个牙科领域,目前拥有及营运由5家位于温州的民营牙科医院所组成的网络。截止今年5月30日止五个月,公司收入按年增长36.1%至4,685.8万元人民币,纯利则增长6.5%至851.8万元人民币。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.